{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338273","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2026-08-06T20:34:51+00:00","discovered_at":"2026-08-06T20:36:18.484639+00:00","generated_at":"2026-08-06T20:36:40.548095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Verrica Q2 net loss $13.2M; YCANTH dispensed units up 28% sequentially, 46% YoY","bullets":["Q2 total revenue $5.9M (down from $12.7M YoY due to $8M milestone in prior year); YCANTH net product revenue $5.1M (+18.7% QoQ, +12.3% YoY).","Q2 net loss $13.2M ($0.62/share) vs net income $0.2M in Q2 2025; non-GAAP net loss $10.2M ($0.48/share).","YCANTH dispensed applicator units reached 19,626 in Q2, up 28.3% QoQ and 46.1% YoY; record quarterly demand.","Entered $27.5M credit facility with Chairman Paul B. Manning; cash runway could extend into 2028.","Phase 3 common warts topline data expected mid-2027; COVE-2 and COVE-3 trials recruiting; settled 2022 class action for $1.7M after insurance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338273","json":"https://secwatch.observer/filing/0001193125-26-338273.json","markdown":"https://secwatch.observer/filing/0001193125-26-338273.md","text":"https://secwatch.observer/filing/0001193125-26-338273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/0001193125-26-338273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:36:40.548095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}